CX3CL1 and Alzheimer disease: Clinical studies suggest that CX3CL1/CX3CR1 may participate to the development of AD pathogenesis: serum fractalkine is elevated in patients with mild AD, and its reduction is positively correlated with the cognitive decline (Kim et al., 2008).